English

    Overview

  • Dr. Aadil Adnan is a Consultant in Nuclear Medicine at Manipal Hospitals, E.M. Bypass, Kolkata, with over five years of experience in advanced molecular imaging and targeted radionuclide therapies. Holding an MBBS and MD, Dr. Adnan specializes in high-dose radionuclide therapy for thyroid, prostate, neuroendocrine, and neural crest tumors, including targeted alpha therapies. 

  • His expertise extends to the conduction and interpretation of PET-CT and Gamma Camera scans, nuclear cardiology procedures, and specialized nuclear oncology and endocrinology practices. A leading expert in theranostics, Dr. Adnan integrates diagnostic imaging with precision-targeted treatment, optimizing patient outcomes in oncology and endocrinology. 

  • His proficiency in radiosynovectomy and other targeted radionuclide therapies underscores his commitment to innovative, minimally invasive treatments for complex diseases. 
  • A life member of the Society of Nuclear Medicine India (SNMI), the Association of Nuclear Medicine Physicians of India (ANMPI), and the Federation of Head and Neck Oncology (FHNO), Dr. Adnan stays at the forefront of advancements in Nuclear medicine. 

  • With a strong focus on precision medicine, molecular imaging, and personalized treatment protocols, he plays a pivotal role in enhancing diagnostic accuracy and therapeutic efficacy for cancer and metabolic disorders. Consult Dr. Aadil Adnan at Manipal Hospitals, Kolkata, for expert nuclear medicine solutions according to your health needs.

    • Fellowship & Membership

  • Life Member of the Society of Nuclear Medicine India (SNMI)
  • Life Member of Association of Nuclear Medicine Physicians of India (ANMPI)
  • Life Member Federation of Head and Neck Oncology (FHNO)

    • Languages Spoken

  • English
  • Bengali
  • Hindi

    • Awards & Achievements

  • Panelist, Medullary Thyroid Carcinoma. NATCON 2019, Kolkata, 20th September 2019, organised by the Indian Association of Surgical Oncology (IASO).
  • Attended Virtual Nuclear Cardiology Elective Live Training from 6th to 17th April 2020, organised by the American Society of Nuclear Cardiology (ASNC).
  • Panelist, Webinar on Multidisciplinary Management of Differentiated Thyroid Cancer, 28th August 2020.
  • Attended web symposium on Management of Thyroid Carcinoma organised by Indian College of Nuclear Medicine from 26th August to 12th September 2020.
  • Attended Nuclear Cardiology Webinar on: Clinical Value of Nuclear Cardiology in Coronary Artery Disease - Advances in Pharmacological Stress Test on 22nd September 2020.
  • Attended e-CME on Thyroid Cancer Management on 5th December 2020, organised by Sanofi.
  • Attended XIX virtual Annual EBM Conference on Evidence Based Management of Cancers in India Technology and Cancer Care - Promise & Reality of the Brave New World from February 26th to 28th and March 5th to 7th, 2021, organised by Tata Memorial Centre, Mumbai.
  • Panelist, Webinar on Prostate Cancer Management: A Multidisciplinary approach on 20th April 2021, organised by Zydus Cadila.
  • Panelist, Webinar on Modern Cancer Treatment: Is Kolkata Ready on 4th February 2022, organised by Medica Hospitals and Rotary Club Calcutta.
  • Speaker and Expert Panelist in the Regional Uro-Oncology Symposium of Eastern India organised by Dr Reddy’s on 10th February 2022. Topic for presentation: What is new in Metastatic Prostate Cancer management?
  • Expert Panelist in the annual conference of Federation of Head and Neck Oncology (FHNO) on 4th November 2022 on: Difficult situations in Differentiated thyroid carcinoma.
  • Speaker at the conference of the Association of SAIL doctors on 05th August 2023, Durgapur. Topic: Evolving role of nuclear medicine in current clinical practices.
  • Speaker at the annual conference of radiographers of Eastern railways, Kolkata on 25th November 2023. Topic: Molecular Imaging and Therapeutic Targeting - the art and science of Theranostics.
  • Speaker in the Medica clinical symposium, Siliguri on 16th December 2023. Topic: Targeted radio-isotope therapy - How it is placed in current clinical practice.
  • Speaker & Expert panelist in 1the 9th Annual Conference of Association of Oncologists of North East India (AONEI) from 2nd to 4th February 2024 at Kohima, Nagaland. Topic: Risk stratification-based management of papillary thyroid carcinoma (Speaker). Topic: Case-based tumour board in locally advanced lung cancer (Panelist).
  • Speaker at the annual conference of the Bengal Urological Society on 6th April 2024 at Kolkata. Topic: Role of radio-isotope therapy in mCRPC: Current evidence and future trends.

    • Talks & Publications

  • Adnan, A., & Basu, S. (2023). Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms. Diagnostics (Basel, Switzerland), 13(13), 2154.
  • Adnan A, Basu S. PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications. Diagnostics (Basel). 2023;13(1):158. Published 2023 Jan 3. doi:10.3390/diagnostics13010158.
  • Adnan A, Raju S, Kumar R, Basu S. An Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non-Thyroid Endocrine Neoplasms. PET Clin. 2022;17(3):343-367.
  • Adnan A, Basu S. Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic Perspective. PET Clin. 2022;17(4):641-652.
  • Adnan A, Basu S. Discordance between Histopathological grading and Dual Tracer PET-CT findings (68Ga-DOTATATE and FDG) in metastatic Neuroendocrine Neoplasms and outcome of 177Lu-DOTATATE PRRT: does in-vivo molecular PET imaging perform better from 'prediction of tumour biology' viewpoint? [published online ahead of print, 2021 Dec 7]. J Nucl Med Technol. 2021;jnmt.121.261998. doi:10.2967/jnmt.121.261998.
  • Adnan A, Basu S. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis. Nucl Med Commun. 2021;42(5):566-574. doi:10.1097/MNM.0000000000001371.
  • Adnan A, Basu S. Combined 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy and Platinum-Based Chemotherapy in Recurrent, Metastatic Sinonasal Neuroendocrine Carcinoma: A Promising Therapeutic Option. J Nucl Med Technol. 2020;48(3):292-294. doi:10.2967/jnmt.119.237354.
  • Adnan A, Basu S. Rare-Site Primary Soft-Tissue Neuroendocrine Tumor with Metastases and Near-Complete Resolution with 177Lu-DOTATATE: Documenting a Promising Clinical Application of Peptide Receptor Radionuclide Therapy. J Nucl Med Technol. 2020;48(1):36‐39. doi:10.2967/jnmt.119.227058.
  • Adnan A, Basu S. Comparison of Dual-Tracer PET and CT Features to Conventional Risk Categories in Assessing Response to 177Lu-PSMA-617 Therapy for Metastatic Prostate Adenocarcinoma with Urinary Bladder Involvement. J Nucl Med Technol. 2020;48(2):148-153. doi:10.2967/jnmt.119.235960.
  • Adnan A, Deep K, Kameswaran M, et al. Biodistribution and Dosimetry of Indigenously Produced 131I-Rituximab in B-Cell Lymphoma: Pilot Study Estimating Patient-Specific Dose Comparing 2 Different Dosimetric Methods. J Nucl Med Technol. 2019;47(4):292‐299. doi:10.2967/jnmt.118.216754.
  • Adnan A, Sampathirao N, Basu S. Implications of fluorodeoxyglucose uptake in low-intermediate grade metastatic neuroendocrine tumors from peptide receptor radionuclide therapy outcome viewpoint: A semi-quantitative standardized uptake value-based analysis. World J Nucl Med. 2019;18(4):389‐395. Published 2019 Dec 18. doi:10.4103/wjnm.WJNM_62_18.
  • Adnan A, Kudachi S, Ramesh S, Prabhash K & Basu S. Metastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factors. Nuclear Medicine Communications. 2019. 40. 1. 10.1097/MNM.0000000000001054.
  • Singha Roy, P., Sengupta, S., Bari, E. A., Nandy, K., & Adnan, A. (2024). Pyrites: A Mystifying Sacral Mass. Journal of pediatric hematology/oncology, 46(2), 114–116.
  • Basu S, Adnan A. Well-differentiated grade 3 neuroendocrine tumours and poorly differentiated grade 3 neuroendocrine carcinomas: will dual tracer PET-computed tomography (68Ga-DOTATATE and FDG) play a pivotal role in differentiation and guiding management strategies?. Nucl Med Commun. 2019;40(10):1086‐1087. doi:10.1097/MNM.0000000000001072.
  • Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, et al. Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy [published online ahead of print, 2020 May 5]. Cancer Biother Radiopharm. 2020;10.1089/cbr.. 2020.3640. doi:10.1089/cbr.2020.3640.

    Fellowship & Membership

  • Life Member of the Society of Nuclear Medicine India (SNMI)
  • Life Member of Association of Nuclear Medicine Physicians of India (ANMPI)
  • Life Member Federation of Head and Neck Oncology (FHNO)

    • Overview

  • Dr. Aadil Adnan is a Consultant in Nuclear Medicine at Manipal Hospitals, E.M. Bypass, Kolkata, with over five years of experience in advanced molecular imaging and targeted radionuclide therapies. Holding an MBBS and MD, Dr. Adnan specializes in high-dose radionuclide therapy for thyroid, prostate, neuroendocrine, and neural crest tumors, including targeted alpha therapies. 

  • His expertise extends to the conduction and interpretation of PET-CT and Gamma Camera scans, nuclear cardiology procedures, and specialized nuclear oncology and endocrinology practices. A leading expert in theranostics, Dr. Adnan integrates diagnostic imaging with precision-targeted treatment, optimizing patient outcomes in oncology and endocrinology. 

  • His proficiency in radiosynovectomy and other targeted radionuclide therapies underscores his commitment to innovative, minimally invasive treatments for complex diseases. 
  • A life member of the Society of Nuclear Medicine India (SNMI), the Association of Nuclear Medicine Physicians of India (ANMPI), and the Federation of Head and Neck Oncology (FHNO), Dr. Adnan stays at the forefront of advancements in Nuclear medicine. 

  • With a strong focus on precision medicine, molecular imaging, and personalized treatment protocols, he plays a pivotal role in enhancing diagnostic accuracy and therapeutic efficacy for cancer and metabolic disorders. Consult Dr. Aadil Adnan at Manipal Hospitals, Kolkata, for expert nuclear medicine solutions according to your health needs.

    • Languages Spoken

  • English
  • Bengali
  • Hindi

    • Awards & Achievements

  • Panelist, Medullary Thyroid Carcinoma. NATCON 2019, Kolkata, 20th September 2019, organised by the Indian Association of Surgical Oncology (IASO).
  • Attended Virtual Nuclear Cardiology Elective Live Training from 6th to 17th April 2020, organised by the American Society of Nuclear Cardiology (ASNC).
  • Panelist, Webinar on Multidisciplinary Management of Differentiated Thyroid Cancer, 28th August 2020.
  • Attended web symposium on Management of Thyroid Carcinoma organised by Indian College of Nuclear Medicine from 26th August to 12th September 2020.
  • Attended Nuclear Cardiology Webinar on: Clinical Value of Nuclear Cardiology in Coronary Artery Disease - Advances in Pharmacological Stress Test on 22nd September 2020.
  • Attended e-CME on Thyroid Cancer Management on 5th December 2020, organised by Sanofi.
  • Attended XIX virtual Annual EBM Conference on Evidence Based Management of Cancers in India Technology and Cancer Care - Promise & Reality of the Brave New World from February 26th to 28th and March 5th to 7th, 2021, organised by Tata Memorial Centre, Mumbai.
  • Panelist, Webinar on Prostate Cancer Management: A Multidisciplinary approach on 20th April 2021, organised by Zydus Cadila.
  • Panelist, Webinar on Modern Cancer Treatment: Is Kolkata Ready on 4th February 2022, organised by Medica Hospitals and Rotary Club Calcutta.
  • Speaker and Expert Panelist in the Regional Uro-Oncology Symposium of Eastern India organised by Dr Reddy’s on 10th February 2022. Topic for presentation: What is new in Metastatic Prostate Cancer management?
  • Expert Panelist in the annual conference of Federation of Head and Neck Oncology (FHNO) on 4th November 2022 on: Difficult situations in Differentiated thyroid carcinoma.
  • Speaker at the conference of the Association of SAIL doctors on 05th August 2023, Durgapur. Topic: Evolving role of nuclear medicine in current clinical practices.
  • Speaker at the annual conference of radiographers of Eastern railways, Kolkata on 25th November 2023. Topic: Molecular Imaging and Therapeutic Targeting - the art and science of Theranostics.
  • Speaker in the Medica clinical symposium, Siliguri on 16th December 2023. Topic: Targeted radio-isotope therapy - How it is placed in current clinical practice.
  • Speaker & Expert panelist in 1the 9th Annual Conference of Association of Oncologists of North East India (AONEI) from 2nd to 4th February 2024 at Kohima, Nagaland. Topic: Risk stratification-based management of papillary thyroid carcinoma (Speaker). Topic: Case-based tumour board in locally advanced lung cancer (Panelist).
  • Speaker at the annual conference of the Bengal Urological Society on 6th April 2024 at Kolkata. Topic: Role of radio-isotope therapy in mCRPC: Current evidence and future trends.

    • Talks & Publications

  • Adnan, A., & Basu, S. (2023). Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms. Diagnostics (Basel, Switzerland), 13(13), 2154.
  • Adnan A, Basu S. PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications. Diagnostics (Basel). 2023;13(1):158. Published 2023 Jan 3. doi:10.3390/diagnostics13010158.
  • Adnan A, Raju S, Kumar R, Basu S. An Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non-Thyroid Endocrine Neoplasms. PET Clin. 2022;17(3):343-367.
  • Adnan A, Basu S. Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic Perspective. PET Clin. 2022;17(4):641-652.
  • Adnan A, Basu S. Discordance between Histopathological grading and Dual Tracer PET-CT findings (68Ga-DOTATATE and FDG) in metastatic Neuroendocrine Neoplasms and outcome of 177Lu-DOTATATE PRRT: does in-vivo molecular PET imaging perform better from 'prediction of tumour biology' viewpoint? [published online ahead of print, 2021 Dec 7]. J Nucl Med Technol. 2021;jnmt.121.261998. doi:10.2967/jnmt.121.261998.
  • Adnan A, Basu S. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis. Nucl Med Commun. 2021;42(5):566-574. doi:10.1097/MNM.0000000000001371.
  • Adnan A, Basu S. Combined 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy and Platinum-Based Chemotherapy in Recurrent, Metastatic Sinonasal Neuroendocrine Carcinoma: A Promising Therapeutic Option. J Nucl Med Technol. 2020;48(3):292-294. doi:10.2967/jnmt.119.237354.
  • Adnan A, Basu S. Rare-Site Primary Soft-Tissue Neuroendocrine Tumor with Metastases and Near-Complete Resolution with 177Lu-DOTATATE: Documenting a Promising Clinical Application of Peptide Receptor Radionuclide Therapy. J Nucl Med Technol. 2020;48(1):36‐39. doi:10.2967/jnmt.119.227058.
  • Adnan A, Basu S. Comparison of Dual-Tracer PET and CT Features to Conventional Risk Categories in Assessing Response to 177Lu-PSMA-617 Therapy for Metastatic Prostate Adenocarcinoma with Urinary Bladder Involvement. J Nucl Med Technol. 2020;48(2):148-153. doi:10.2967/jnmt.119.235960.
  • Adnan A, Deep K, Kameswaran M, et al. Biodistribution and Dosimetry of Indigenously Produced 131I-Rituximab in B-Cell Lymphoma: Pilot Study Estimating Patient-Specific Dose Comparing 2 Different Dosimetric Methods. J Nucl Med Technol. 2019;47(4):292‐299. doi:10.2967/jnmt.118.216754.
  • Adnan A, Sampathirao N, Basu S. Implications of fluorodeoxyglucose uptake in low-intermediate grade metastatic neuroendocrine tumors from peptide receptor radionuclide therapy outcome viewpoint: A semi-quantitative standardized uptake value-based analysis. World J Nucl Med. 2019;18(4):389‐395. Published 2019 Dec 18. doi:10.4103/wjnm.WJNM_62_18.
  • Adnan A, Kudachi S, Ramesh S, Prabhash K & Basu S. Metastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factors. Nuclear Medicine Communications. 2019. 40. 1. 10.1097/MNM.0000000000001054.
  • Singha Roy, P., Sengupta, S., Bari, E. A., Nandy, K., & Adnan, A. (2024). Pyrites: A Mystifying Sacral Mass. Journal of pediatric hematology/oncology, 46(2), 114–116.
  • Basu S, Adnan A. Well-differentiated grade 3 neuroendocrine tumours and poorly differentiated grade 3 neuroendocrine carcinomas: will dual tracer PET-computed tomography (68Ga-DOTATATE and FDG) play a pivotal role in differentiation and guiding management strategies?. Nucl Med Commun. 2019;40(10):1086‐1087. doi:10.1097/MNM.0000000000001072.
  • Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, et al. Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy [published online ahead of print, 2020 May 5]. Cancer Biother Radiopharm. 2020;10.1089/cbr.. 2020.3640. doi:10.1089/cbr.2020.3640.

    Languages Spoken

  • English
  • Bengali
  • Hindi

    • Overview

  • Dr. Aadil Adnan is a Consultant in Nuclear Medicine at Manipal Hospitals, E.M. Bypass, Kolkata, with over five years of experience in advanced molecular imaging and targeted radionuclide therapies. Holding an MBBS and MD, Dr. Adnan specializes in high-dose radionuclide therapy for thyroid, prostate, neuroendocrine, and neural crest tumors, including targeted alpha therapies. 

  • His expertise extends to the conduction and interpretation of PET-CT and Gamma Camera scans, nuclear cardiology procedures, and specialized nuclear oncology and endocrinology practices. A leading expert in theranostics, Dr. Adnan integrates diagnostic imaging with precision-targeted treatment, optimizing patient outcomes in oncology and endocrinology. 

  • His proficiency in radiosynovectomy and other targeted radionuclide therapies underscores his commitment to innovative, minimally invasive treatments for complex diseases. 
  • A life member of the Society of Nuclear Medicine India (SNMI), the Association of Nuclear Medicine Physicians of India (ANMPI), and the Federation of Head and Neck Oncology (FHNO), Dr. Adnan stays at the forefront of advancements in Nuclear medicine. 

  • With a strong focus on precision medicine, molecular imaging, and personalized treatment protocols, he plays a pivotal role in enhancing diagnostic accuracy and therapeutic efficacy for cancer and metabolic disorders. Consult Dr. Aadil Adnan at Manipal Hospitals, Kolkata, for expert nuclear medicine solutions according to your health needs.

    • Fellowship & Membership

  • Life Member of the Society of Nuclear Medicine India (SNMI)
  • Life Member of Association of Nuclear Medicine Physicians of India (ANMPI)
  • Life Member Federation of Head and Neck Oncology (FHNO)

    • Awards & Achievements

  • Panelist, Medullary Thyroid Carcinoma. NATCON 2019, Kolkata, 20th September 2019, organised by the Indian Association of Surgical Oncology (IASO).
  • Attended Virtual Nuclear Cardiology Elective Live Training from 6th to 17th April 2020, organised by the American Society of Nuclear Cardiology (ASNC).
  • Panelist, Webinar on Multidisciplinary Management of Differentiated Thyroid Cancer, 28th August 2020.
  • Attended web symposium on Management of Thyroid Carcinoma organised by Indian College of Nuclear Medicine from 26th August to 12th September 2020.
  • Attended Nuclear Cardiology Webinar on: Clinical Value of Nuclear Cardiology in Coronary Artery Disease - Advances in Pharmacological Stress Test on 22nd September 2020.
  • Attended e-CME on Thyroid Cancer Management on 5th December 2020, organised by Sanofi.
  • Attended XIX virtual Annual EBM Conference on Evidence Based Management of Cancers in India Technology and Cancer Care - Promise & Reality of the Brave New World from February 26th to 28th and March 5th to 7th, 2021, organised by Tata Memorial Centre, Mumbai.
  • Panelist, Webinar on Prostate Cancer Management: A Multidisciplinary approach on 20th April 2021, organised by Zydus Cadila.
  • Panelist, Webinar on Modern Cancer Treatment: Is Kolkata Ready on 4th February 2022, organised by Medica Hospitals and Rotary Club Calcutta.
  • Speaker and Expert Panelist in the Regional Uro-Oncology Symposium of Eastern India organised by Dr Reddy’s on 10th February 2022. Topic for presentation: What is new in Metastatic Prostate Cancer management?
  • Expert Panelist in the annual conference of Federation of Head and Neck Oncology (FHNO) on 4th November 2022 on: Difficult situations in Differentiated thyroid carcinoma.
  • Speaker at the conference of the Association of SAIL doctors on 05th August 2023, Durgapur. Topic: Evolving role of nuclear medicine in current clinical practices.
  • Speaker at the annual conference of radiographers of Eastern railways, Kolkata on 25th November 2023. Topic: Molecular Imaging and Therapeutic Targeting - the art and science of Theranostics.
  • Speaker in the Medica clinical symposium, Siliguri on 16th December 2023. Topic: Targeted radio-isotope therapy - How it is placed in current clinical practice.
  • Speaker & Expert panelist in 1the 9th Annual Conference of Association of Oncologists of North East India (AONEI) from 2nd to 4th February 2024 at Kohima, Nagaland. Topic: Risk stratification-based management of papillary thyroid carcinoma (Speaker). Topic: Case-based tumour board in locally advanced lung cancer (Panelist).
  • Speaker at the annual conference of the Bengal Urological Society on 6th April 2024 at Kolkata. Topic: Role of radio-isotope therapy in mCRPC: Current evidence and future trends.

    • Talks & Publications

  • Adnan, A., & Basu, S. (2023). Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms. Diagnostics (Basel, Switzerland), 13(13), 2154.
  • Adnan A, Basu S. PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications. Diagnostics (Basel). 2023;13(1):158. Published 2023 Jan 3. doi:10.3390/diagnostics13010158.
  • Adnan A, Raju S, Kumar R, Basu S. An Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non-Thyroid Endocrine Neoplasms. PET Clin. 2022;17(3):343-367.
  • Adnan A, Basu S. Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic Perspective. PET Clin. 2022;17(4):641-652.
  • Adnan A, Basu S. Discordance between Histopathological grading and Dual Tracer PET-CT findings (68Ga-DOTATATE and FDG) in metastatic Neuroendocrine Neoplasms and outcome of 177Lu-DOTATATE PRRT: does in-vivo molecular PET imaging perform better from 'prediction of tumour biology' viewpoint? [published online ahead of print, 2021 Dec 7]. J Nucl Med Technol. 2021;jnmt.121.261998. doi:10.2967/jnmt.121.261998.
  • Adnan A, Basu S. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis. Nucl Med Commun. 2021;42(5):566-574. doi:10.1097/MNM.0000000000001371.
  • Adnan A, Basu S. Combined 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy and Platinum-Based Chemotherapy in Recurrent, Metastatic Sinonasal Neuroendocrine Carcinoma: A Promising Therapeutic Option. J Nucl Med Technol. 2020;48(3):292-294. doi:10.2967/jnmt.119.237354.
  • Adnan A, Basu S. Rare-Site Primary Soft-Tissue Neuroendocrine Tumor with Metastases and Near-Complete Resolution with 177Lu-DOTATATE: Documenting a Promising Clinical Application of Peptide Receptor Radionuclide Therapy. J Nucl Med Technol. 2020;48(1):36‐39. doi:10.2967/jnmt.119.227058.
  • Adnan A, Basu S. Comparison of Dual-Tracer PET and CT Features to Conventional Risk Categories in Assessing Response to 177Lu-PSMA-617 Therapy for Metastatic Prostate Adenocarcinoma with Urinary Bladder Involvement. J Nucl Med Technol. 2020;48(2):148-153. doi:10.2967/jnmt.119.235960.
  • Adnan A, Deep K, Kameswaran M, et al. Biodistribution and Dosimetry of Indigenously Produced 131I-Rituximab in B-Cell Lymphoma: Pilot Study Estimating Patient-Specific Dose Comparing 2 Different Dosimetric Methods. J Nucl Med Technol. 2019;47(4):292‐299. doi:10.2967/jnmt.118.216754.
  • Adnan A, Sampathirao N, Basu S. Implications of fluorodeoxyglucose uptake in low-intermediate grade metastatic neuroendocrine tumors from peptide receptor radionuclide therapy outcome viewpoint: A semi-quantitative standardized uptake value-based analysis. World J Nucl Med. 2019;18(4):389‐395. Published 2019 Dec 18. doi:10.4103/wjnm.WJNM_62_18.
  • Adnan A, Kudachi S, Ramesh S, Prabhash K & Basu S. Metastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factors. Nuclear Medicine Communications. 2019. 40. 1. 10.1097/MNM.0000000000001054.
  • Singha Roy, P., Sengupta, S., Bari, E. A., Nandy, K., & Adnan, A. (2024). Pyrites: A Mystifying Sacral Mass. Journal of pediatric hematology/oncology, 46(2), 114–116.
  • Basu S, Adnan A. Well-differentiated grade 3 neuroendocrine tumours and poorly differentiated grade 3 neuroendocrine carcinomas: will dual tracer PET-computed tomography (68Ga-DOTATATE and FDG) play a pivotal role in differentiation and guiding management strategies?. Nucl Med Commun. 2019;40(10):1086‐1087. doi:10.1097/MNM.0000000000001072.
  • Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, et al. Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy [published online ahead of print, 2020 May 5]. Cancer Biother Radiopharm. 2020;10.1089/cbr.. 2020.3640. doi:10.1089/cbr.2020.3640.

    Awards & Achievements

  • Panelist, Medullary Thyroid Carcinoma. NATCON 2019, Kolkata, 20th September 2019, organised by the Indian Association of Surgical Oncology (IASO).
  • Attended Virtual Nuclear Cardiology Elective Live Training from 6th to 17th April 2020, organised by the American Society of Nuclear Cardiology (ASNC).
  • Panelist, Webinar on Multidisciplinary Management of Differentiated Thyroid Cancer, 28th August 2020.
  • Attended web symposium on Management of Thyroid Carcinoma organised by Indian College of Nuclear Medicine from 26th August to 12th September 2020.
  • Attended Nuclear Cardiology Webinar on: Clinical Value of Nuclear Cardiology in Coronary Artery Disease - Advances in Pharmacological Stress Test on 22nd September 2020.
  • Attended e-CME on Thyroid Cancer Management on 5th December 2020, organised by Sanofi.
  • Attended XIX virtual Annual EBM Conference on Evidence Based Management of Cancers in India Technology and Cancer Care - Promise & Reality of the Brave New World from February 26th to 28th and March 5th to 7th, 2021, organised by Tata Memorial Centre, Mumbai.
  • Panelist, Webinar on Prostate Cancer Management: A Multidisciplinary approach on 20th April 2021, organised by Zydus Cadila.
  • Panelist, Webinar on Modern Cancer Treatment: Is Kolkata Ready on 4th February 2022, organised by Medica Hospitals and Rotary Club Calcutta.
  • Speaker and Expert Panelist in the Regional Uro-Oncology Symposium of Eastern India organised by Dr Reddy’s on 10th February 2022. Topic for presentation: What is new in Metastatic Prostate Cancer management?
  • Expert Panelist in the annual conference of Federation of Head and Neck Oncology (FHNO) on 4th November 2022 on: Difficult situations in Differentiated thyroid carcinoma.
  • Speaker at the conference of the Association of SAIL doctors on 05th August 2023, Durgapur. Topic: Evolving role of nuclear medicine in current clinical practices.
  • Speaker at the annual conference of radiographers of Eastern railways, Kolkata on 25th November 2023. Topic: Molecular Imaging and Therapeutic Targeting - the art and science of Theranostics.
  • Speaker in the Medica clinical symposium, Siliguri on 16th December 2023. Topic: Targeted radio-isotope therapy - How it is placed in current clinical practice.
  • Speaker & Expert panelist in 1the 9th Annual Conference of Association of Oncologists of North East India (AONEI) from 2nd to 4th February 2024 at Kohima, Nagaland. Topic: Risk stratification-based management of papillary thyroid carcinoma (Speaker). Topic: Case-based tumour board in locally advanced lung cancer (Panelist).
  • Speaker at the annual conference of the Bengal Urological Society on 6th April 2024 at Kolkata. Topic: Role of radio-isotope therapy in mCRPC: Current evidence and future trends.

    • Fellowship & Membership

  • Life Member of the Society of Nuclear Medicine India (SNMI)
  • Life Member of Association of Nuclear Medicine Physicians of India (ANMPI)
  • Life Member Federation of Head and Neck Oncology (FHNO)

    • Languages Spoken

  • English
  • Bengali
  • Hindi

    • Talks & Publications

  • Adnan, A., & Basu, S. (2023). Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms. Diagnostics (Basel, Switzerland), 13(13), 2154.
  • Adnan A, Basu S. PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications. Diagnostics (Basel). 2023;13(1):158. Published 2023 Jan 3. doi:10.3390/diagnostics13010158.
  • Adnan A, Raju S, Kumar R, Basu S. An Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non-Thyroid Endocrine Neoplasms. PET Clin. 2022;17(3):343-367.
  • Adnan A, Basu S. Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic Perspective. PET Clin. 2022;17(4):641-652.
  • Adnan A, Basu S. Discordance between Histopathological grading and Dual Tracer PET-CT findings (68Ga-DOTATATE and FDG) in metastatic Neuroendocrine Neoplasms and outcome of 177Lu-DOTATATE PRRT: does in-vivo molecular PET imaging perform better from 'prediction of tumour biology' viewpoint? [published online ahead of print, 2021 Dec 7]. J Nucl Med Technol. 2021;jnmt.121.261998. doi:10.2967/jnmt.121.261998.
  • Adnan A, Basu S. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis. Nucl Med Commun. 2021;42(5):566-574. doi:10.1097/MNM.0000000000001371.
  • Adnan A, Basu S. Combined 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy and Platinum-Based Chemotherapy in Recurrent, Metastatic Sinonasal Neuroendocrine Carcinoma: A Promising Therapeutic Option. J Nucl Med Technol. 2020;48(3):292-294. doi:10.2967/jnmt.119.237354.
  • Adnan A, Basu S. Rare-Site Primary Soft-Tissue Neuroendocrine Tumor with Metastases and Near-Complete Resolution with 177Lu-DOTATATE: Documenting a Promising Clinical Application of Peptide Receptor Radionuclide Therapy. J Nucl Med Technol. 2020;48(1):36‐39. doi:10.2967/jnmt.119.227058.
  • Adnan A, Basu S. Comparison of Dual-Tracer PET and CT Features to Conventional Risk Categories in Assessing Response to 177Lu-PSMA-617 Therapy for Metastatic Prostate Adenocarcinoma with Urinary Bladder Involvement. J Nucl Med Technol. 2020;48(2):148-153. doi:10.2967/jnmt.119.235960.
  • Adnan A, Deep K, Kameswaran M, et al. Biodistribution and Dosimetry of Indigenously Produced 131I-Rituximab in B-Cell Lymphoma: Pilot Study Estimating Patient-Specific Dose Comparing 2 Different Dosimetric Methods. J Nucl Med Technol. 2019;47(4):292‐299. doi:10.2967/jnmt.118.216754.
  • Adnan A, Sampathirao N, Basu S. Implications of fluorodeoxyglucose uptake in low-intermediate grade metastatic neuroendocrine tumors from peptide receptor radionuclide therapy outcome viewpoint: A semi-quantitative standardized uptake value-based analysis. World J Nucl Med. 2019;18(4):389‐395. Published 2019 Dec 18. doi:10.4103/wjnm.WJNM_62_18.
  • Adnan A, Kudachi S, Ramesh S, Prabhash K & Basu S. Metastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factors. Nuclear Medicine Communications. 2019. 40. 1. 10.1097/MNM.0000000000001054.
  • Singha Roy, P., Sengupta, S., Bari, E. A., Nandy, K., & Adnan, A. (2024). Pyrites: A Mystifying Sacral Mass. Journal of pediatric hematology/oncology, 46(2), 114–116.
  • Basu S, Adnan A. Well-differentiated grade 3 neuroendocrine tumours and poorly differentiated grade 3 neuroendocrine carcinomas: will dual tracer PET-computed tomography (68Ga-DOTATATE and FDG) play a pivotal role in differentiation and guiding management strategies?. Nucl Med Commun. 2019;40(10):1086‐1087. doi:10.1097/MNM.0000000000001072.
  • Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, et al. Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy [published online ahead of print, 2020 May 5]. Cancer Biother Radiopharm. 2020;10.1089/cbr.. 2020.3640. doi:10.1089/cbr.2020.3640.

    • Overview

  • Dr. Aadil Adnan is a Consultant in Nuclear Medicine at Manipal Hospitals, E.M. Bypass, Kolkata, with over five years of experience in advanced molecular imaging and targeted radionuclide therapies. Holding an MBBS and MD, Dr. Adnan specializes in high-dose radionuclide therapy for thyroid, prostate, neuroendocrine, and neural crest tumors, including targeted alpha therapies. 

  • His expertise extends to the conduction and interpretation of PET-CT and Gamma Camera scans, nuclear cardiology procedures, and specialized nuclear oncology and endocrinology practices. A leading expert in theranostics, Dr. Adnan integrates diagnostic imaging with precision-targeted treatment, optimizing patient outcomes in oncology and endocrinology. 

  • His proficiency in radiosynovectomy and other targeted radionuclide therapies underscores his commitment to innovative, minimally invasive treatments for complex diseases. 
  • A life member of the Society of Nuclear Medicine India (SNMI), the Association of Nuclear Medicine Physicians of India (ANMPI), and the Federation of Head and Neck Oncology (FHNO), Dr. Adnan stays at the forefront of advancements in Nuclear medicine. 

  • With a strong focus on precision medicine, molecular imaging, and personalized treatment protocols, he plays a pivotal role in enhancing diagnostic accuracy and therapeutic efficacy for cancer and metabolic disorders. Consult Dr. Aadil Adnan at Manipal Hospitals, Kolkata, for expert nuclear medicine solutions according to your health needs.

    Talks & Publications

  • Adnan, A., & Basu, S. (2023). Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms. Diagnostics (Basel, Switzerland), 13(13), 2154.
  • Adnan A, Basu S. PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications. Diagnostics (Basel). 2023;13(1):158. Published 2023 Jan 3. doi:10.3390/diagnostics13010158.
  • Adnan A, Raju S, Kumar R, Basu S. An Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non-Thyroid Endocrine Neoplasms. PET Clin. 2022;17(3):343-367.
  • Adnan A, Basu S. Dual-Tracer PET-Computed Tomography Imaging for Precision Radio-Molecular Theranostics of Prostate Cancer: A Futuristic Perspective. PET Clin. 2022;17(4):641-652.
  • Adnan A, Basu S. Discordance between Histopathological grading and Dual Tracer PET-CT findings (68Ga-DOTATATE and FDG) in metastatic Neuroendocrine Neoplasms and outcome of 177Lu-DOTATATE PRRT: does in-vivo molecular PET imaging perform better from 'prediction of tumour biology' viewpoint? [published online ahead of print, 2021 Dec 7]. J Nucl Med Technol. 2021;jnmt.121.261998. doi:10.2967/jnmt.121.261998.
  • Adnan A, Basu S. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system ('Pro-PET' score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis. Nucl Med Commun. 2021;42(5):566-574. doi:10.1097/MNM.0000000000001371.
  • Adnan A, Basu S. Combined 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy and Platinum-Based Chemotherapy in Recurrent, Metastatic Sinonasal Neuroendocrine Carcinoma: A Promising Therapeutic Option. J Nucl Med Technol. 2020;48(3):292-294. doi:10.2967/jnmt.119.237354.
  • Adnan A, Basu S. Rare-Site Primary Soft-Tissue Neuroendocrine Tumor with Metastases and Near-Complete Resolution with 177Lu-DOTATATE: Documenting a Promising Clinical Application of Peptide Receptor Radionuclide Therapy. J Nucl Med Technol. 2020;48(1):36‐39. doi:10.2967/jnmt.119.227058.
  • Adnan A, Basu S. Comparison of Dual-Tracer PET and CT Features to Conventional Risk Categories in Assessing Response to 177Lu-PSMA-617 Therapy for Metastatic Prostate Adenocarcinoma with Urinary Bladder Involvement. J Nucl Med Technol. 2020;48(2):148-153. doi:10.2967/jnmt.119.235960.
  • Adnan A, Deep K, Kameswaran M, et al. Biodistribution and Dosimetry of Indigenously Produced 131I-Rituximab in B-Cell Lymphoma: Pilot Study Estimating Patient-Specific Dose Comparing 2 Different Dosimetric Methods. J Nucl Med Technol. 2019;47(4):292‐299. doi:10.2967/jnmt.118.216754.
  • Adnan A, Sampathirao N, Basu S. Implications of fluorodeoxyglucose uptake in low-intermediate grade metastatic neuroendocrine tumors from peptide receptor radionuclide therapy outcome viewpoint: A semi-quantitative standardized uptake value-based analysis. World J Nucl Med. 2019;18(4):389‐395. Published 2019 Dec 18. doi:10.4103/wjnm.WJNM_62_18.
  • Adnan A, Kudachi S, Ramesh S, Prabhash K & Basu S. Metastatic or locally advanced mediastinal neuroendocrine tumours: outcome with 177Lu-DOTATATE-based peptide receptor radionuclide therapy and assessment of prognostic factors. Nuclear Medicine Communications. 2019. 40. 1. 10.1097/MNM.0000000000001054.
  • Singha Roy, P., Sengupta, S., Bari, E. A., Nandy, K., & Adnan, A. (2024). Pyrites: A Mystifying Sacral Mass. Journal of pediatric hematology/oncology, 46(2), 114–116.
  • Basu S, Adnan A. Well-differentiated grade 3 neuroendocrine tumours and poorly differentiated grade 3 neuroendocrine carcinomas: will dual tracer PET-computed tomography (68Ga-DOTATATE and FDG) play a pivotal role in differentiation and guiding management strategies?. Nucl Med Commun. 2019;40(10):1086‐1087. doi:10.1097/MNM.0000000000001072.
  • Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, et al. Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy [published online ahead of print, 2020 May 5]. Cancer Biother Radiopharm. 2020;10.1089/cbr.. 2020.3640. doi:10.1089/cbr.2020.3640.

    • Overview

  • Dr. Aadil Adnan is a Consultant in Nuclear Medicine at Manipal Hospitals, E.M. Bypass, Kolkata, with over five years of experience in advanced molecular imaging and targeted radionuclide therapies. Holding an MBBS and MD, Dr. Adnan specializes in high-dose radionuclide therapy for thyroid, prostate, neuroendocrine, and neural crest tumors, including targeted alpha therapies. 

  • His expertise extends to the conduction and interpretation of PET-CT and Gamma Camera scans, nuclear cardiology procedures, and specialized nuclear oncology and endocrinology practices. A leading expert in theranostics, Dr. Adnan integrates diagnostic imaging with precision-targeted treatment, optimizing patient outcomes in oncology and endocrinology. 

  • His proficiency in radiosynovectomy and other targeted radionuclide therapies underscores his commitment to innovative, minimally invasive treatments for complex diseases. 
  • A life member of the Society of Nuclear Medicine India (SNMI), the Association of Nuclear Medicine Physicians of India (ANMPI), and the Federation of Head and Neck Oncology (FHNO), Dr. Adnan stays at the forefront of advancements in Nuclear medicine. 

  • With a strong focus on precision medicine, molecular imaging, and personalized treatment protocols, he plays a pivotal role in enhancing diagnostic accuracy and therapeutic efficacy for cancer and metabolic disorders. Consult Dr. Aadil Adnan at Manipal Hospitals, Kolkata, for expert nuclear medicine solutions according to your health needs.

    • Fellowship & Membership

  • Life Member of the Society of Nuclear Medicine India (SNMI)
  • Life Member of Association of Nuclear Medicine Physicians of India (ANMPI)
  • Life Member Federation of Head and Neck Oncology (FHNO)

    • Languages Spoken

  • English
  • Bengali
  • Hindi

    • Awards & Achievements

  • Panelist, Medullary Thyroid Carcinoma. NATCON 2019, Kolkata, 20th September 2019, organised by the Indian Association of Surgical Oncology (IASO).
  • Attended Virtual Nuclear Cardiology Elective Live Training from 6th to 17th April 2020, organised by the American Society of Nuclear Cardiology (ASNC).
  • Panelist, Webinar on Multidisciplinary Management of Differentiated Thyroid Cancer, 28th August 2020.
  • Attended web symposium on Management of Thyroid Carcinoma organised by Indian College of Nuclear Medicine from 26th August to 12th September 2020.
  • Attended Nuclear Cardiology Webinar on: Clinical Value of Nuclear Cardiology in Coronary Artery Disease - Advances in Pharmacological Stress Test on 22nd September 2020.
  • Attended e-CME on Thyroid Cancer Management on 5th December 2020, organised by Sanofi.
  • Attended XIX virtual Annual EBM Conference on Evidence Based Management of Cancers in India Technology and Cancer Care - Promise & Reality of the Brave New World from February 26th to 28th and March 5th to 7th, 2021, organised by Tata Memorial Centre, Mumbai.
  • Panelist, Webinar on Prostate Cancer Management: A Multidisciplinary approach on 20th April 2021, organised by Zydus Cadila.
  • Panelist, Webinar on Modern Cancer Treatment: Is Kolkata Ready on 4th February 2022, organised by Medica Hospitals and Rotary Club Calcutta.
  • Speaker and Expert Panelist in the Regional Uro-Oncology Symposium of Eastern India organised by Dr Reddy’s on 10th February 2022. Topic for presentation: What is new in Metastatic Prostate Cancer management?
  • Expert Panelist in the annual conference of Federation of Head and Neck Oncology (FHNO) on 4th November 2022 on: Difficult situations in Differentiated thyroid carcinoma.
  • Speaker at the conference of the Association of SAIL doctors on 05th August 2023, Durgapur. Topic: Evolving role of nuclear medicine in current clinical practices.
  • Speaker at the annual conference of radiographers of Eastern railways, Kolkata on 25th November 2023. Topic: Molecular Imaging and Therapeutic Targeting - the art and science of Theranostics.
  • Speaker in the Medica clinical symposium, Siliguri on 16th December 2023. Topic: Targeted radio-isotope therapy - How it is placed in current clinical practice.
  • Speaker & Expert panelist in 1the 9th Annual Conference of Association of Oncologists of North East India (AONEI) from 2nd to 4th February 2024 at Kohima, Nagaland. Topic: Risk stratification-based management of papillary thyroid carcinoma (Speaker). Topic: Case-based tumour board in locally advanced lung cancer (Panelist).
  • Speaker at the annual conference of the Bengal Urological Society on 6th April 2024 at Kolkata. Topic: Role of radio-isotope therapy in mCRPC: Current evidence and future trends.

FAQ's

Patients often seek Dr. Aadil Adnan’s expertise as the Consultant - Nuclear Medicine at Manipal Hospitals EM Bypass. Consult Dr. Aadil Adnan, Nuclear Medicine Specialist in EM Bypass Kolkata, for precise scans and imaging. Book your appointment now at Manipal Hospitals EM Bypass.

Home Em-bypass Doctors Dr-aadil-adnan-nuclear-medicine-specialist

Appointment
Health Check
Contact Us
review icon
Review Us
Call Us